Antimicrobial Resistance Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 to 2032

Antimicrobial Resistance Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 to 2032

The Global Antimicrobial Resistance Diagnostics Market was valued at USD 4.4 billion in 2023 and is projected to expand at a CAGR of over 6.3% from 2024 to 2032. The market is driven by the growing incidence of antibiotic-resistant infections, the increasing demand for personalized treatments, and significant advancements in diagnostic technologies.

The market is divided into two main product categories: instruments & consumables and kits & reagents. In 2023, the kits & reagents segment led the market with a value of USD 2.8 billion. These diagnostic kits and reagents play a crucial role in the rapid and accurate identification of antibiotic-resistant bacterial strains. Early detection of resistance is essential for ensuring effective treatment regimens and reducing the overuse of antibiotics, which is a primary factor in the development of resistance. Global and regional efforts, such as initiatives from health organizations, are further driving the demand for AMR diagnostic tools.

When examining the technologies used in antimicrobial resistance diagnostics, the market is segmented into microbiology culture, immunoassay, PCR, next-generation sequencing (NGS), mass spectrometry, rapid & point-of-care diagnostics, and other technologies. The microbiology culture segment held a significant share of 31.1% in 2023. Technological advancements in microbial culture have greatly improved the speed, accuracy, and specificity of identifying resistant strains. The automation of culture systems has notably reduced the time required for diagnostics, making culture-based methods more reliable in detecting antibiotic-resistant bacteria, which is expected to further propel market growth.

U.S. antimicrobial resistance diagnostic market is projected to grow at a CAGR of 6.2%, reaching USD 3.1 billion by 2032. U.S. government initiatives focused on combating antibiotic resistance, such as the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB), have contributed to the expansion of AMR diagnostic capabilities. These initiatives support advancements in diagnostic technologies and provide funding for research and development in the field. Additionally, the U.S. Department of Health and Human Services has committed substantial investments to enhance AMR diagnostics, research, and the development of novel antibiotics, further boosting market growth.